His research is aimed at developing high-precision neurodiagnostic procedures, multidimensional clinical outcome assessment approaches and targeted therapeutic interventions for persons with severe acquired brain injury and disorders of consciousness. His teams have produced widely-recognized assessment tools such as the Coma Recovery Scale-Revised and identified the only available treatment (ie, amantadine hydrochloride) proven to accelerate the pace of recovery following severe TBI. He led the expert panels that developed the diagnostic criteria for the minimally conscious state (Aspen Workgroup, 2002), the 2018 Practice Guideline Update on Disorders of Consciousness (American Academy of Neurology-ACRM-NIDILRR) and the 2020 ACRM-NIDILRR Minimum Competency Recommendations for Programs that Provide Rehabilitation Services for Persons with Disorders of Consciousness. Dr. Giacino has published over 170 articles and book chapters and is the recipient of the ACRM Brain Injury Special Interest Group’s Lifetime Achievement Award, Brain Injury Association of America’s William Fields Caveness Award and the University of Texas Medical Branch’s Robert L. Moody Prize.